首页> 中文期刊> 《天津医药》 >终末期肝病评分模型在评价慢性肝衰竭人工肝治疗效果中的应用

终末期肝病评分模型在评价慢性肝衰竭人工肝治疗效果中的应用

         

摘要

Objective To investigate the value of model for end-stage liver disease (MELD) score, MELD with in-corporation of serum sodium (MELD-Na) score and integrated MELD (iMELD) score for evaluation of prognosis of chronic liver failure. Methods A total of 159 consecutive patients with chronic liver failure were included in the study and divided into two groups (death group and survival group) according to the prognosis. The levels of total bilirubin (TBIL), serum creati-nine (Cr), prothrombin time (PT), PT international normalized ratio (INR), serum sodium (Na+), age, MELD, MELD-Na and iMELD were calculated respectively and the comparative analysis was performed. Areas under the receiver operating charac-teristic curve (AUC-ROC) of MELD, MELD-Na and iMELD were used to assess the prognosis in patients with chronic liver failure. Results The values of TBIL (μmol/L:330.9±181.9 vs 245.5±127.7),Cr (μmol/L:84.9±63.8 vs 81.2±49.3),INR (2.50±1.01 vs 2.09±0.57),MELD (26.2±6.5 vs 22.0±5.8),MELD-Na (35.9±31.5 vs 25.3±8.7) and iMELD (49.5±17.4 vs 42.4±10.9) were significantly higher in death group than those in survival group (P < 0.01). The serum level of Na+ was signif- icantly lower in death group than that of survival group (P < 0.01). The mortality of liver failure was higher in patients with the increased scores of MELD, MELD-Na and iMELD. The area under curve (AUC) values generated by the ROC curves was no difference respectively (P > 0.05) for MELD score (AUC=0.691), MELD-Na score (AUC=0.690) and iMELD score (AUC= 0.674) . The cut-off scores of three systems were 25.8 (MELD), 31.0 (MELD-Na) and 53.5 (iMELD) respectively, which could discriminate higher and lower mortality accurately. Conclusion MELD, MELD-Na and iMELD scores can predict short-term clinical outcomes of liver failure patients undergoing artificial liver comprehensive medical treatment.%目的:比较终末期肝病模型(MELD)、MELD-Na模型、iMELD模型评分系统预测慢性肝功能衰竭患者短期(治疗3个月)预后的价值。方法选取159例乙肝后慢性肝衰竭患者,以治疗3个月后患者恢复状态分成存活组(108例)和死亡组(51例)。比较2组治疗前的总胆红素(TBIL)、肌酐(Cr)、凝血酶原时间(PT)、PT的国际标准化比率(INR)、血清钠(Na+)、MELD、MELD-Na和iMELD评分值。计算受试者工作特征(ROC)曲线下的面积来进一步评价MELD模型、MELD-Na评分及iMELD评分对乙肝后慢性肝衰竭人工肝治疗3个月后预后的预测价值。结果死亡组较存活组的TBIL(μmol/L:330.9±181.9 vs 245.5±127.7)、Cr(μmol/L:84.9±63.8 vs 81.2±49.3)、INR(2.50±1.01 vs 2.09±0.57)、MELD(26.2±6.5 vs 22.0±5.8)、MELD-Na(35.9±31.5 vs 25.3±8.7)及iMELD评分(49.5±17.4 vs 42.4±10.9)增高,血清Na+水平(mmol/L:131.9±24.1 vs 133.8±11.0)降低(P<0.01)。患者病死率随着MELD、MELD-Na和iMELD评分升高而增加。MELD、MELD-Na及iMELD评分预测乙肝后慢性肝衰竭患者近期死亡危险性的最佳临界值分别为25.8、31.0和53.5。3种评分的曲线下面积(AUC)差异均无统计学意义。结论 MELD、MELD-Na和iMELD评分均能较好地预测肝衰竭患者经过人工肝联合内科综合治疗后的短期临床预后。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号